Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.7%

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s share price fell 5.7% during trading on Monday . The stock traded as low as $14.86 and last traded at $14.95. 55,230 shares traded hands during trading, a decline of 94% from the average session volume of 882,622 shares. The stock had previously closed at $15.86.

Wall Street Analyst Weigh In

Several research firms have commented on STOK. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Friday, June 28th. Wedbush reissued an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, May 7th. Finally, Canaccord Genuity Group lowered their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $20.57.

Stoke Therapeutics Trading Down 6.7 %

The business’s fifty day simple moving average is $14.54 and its 200-day simple moving average is $10.66. The firm has a market cap of $771.39 million, a P/E ratio of -6.04 and a beta of 0.87.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, May 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The business had revenue of $4.22 million for the quarter, compared to the consensus estimate of $3.33 million. As a group, research analysts expect that Stoke Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total transaction of $137,500.00. Following the sale, the insider now owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its position in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Stoke Therapeutics by 5.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock valued at $425,000 after purchasing an additional 1,642 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics during the 2nd quarter valued at $123,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Stoke Therapeutics during the 1st quarter valued at $141,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.